MEDICAMEQ — Medicamen Biotech Cashflow Statement
0.000.00%
- IN₹5.59bn
- IN₹5.73bn
- IN₹1.79bn
- 80
- 12
- 60
- 51
Annual cashflow statement for Medicamen Biotech, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
R2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Interim Report | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 61.7 | 121 | 149 | 147 | 94.9 |
Depreciation | |||||
Non-Cash Items | 20.5 | 51.7 | 44.6 | 45.1 | 72.5 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 53.8 | -70.5 | -210 | -319 | -306 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 149 | 128 | 41.1 | -62.9 | -67.4 |
Capital Expenditures | -198 | -180 | -86.1 | -66 | -62.9 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 4.16 | 1.53 | 1.35 | 7.21 | 7.24 |
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -193 | -178 | -84.7 | -58.8 | -55.6 |
Financing Cash Flow Items | -24.8 | -9.09 | -15 | -28.5 | -9.53 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 22.5 | 58.4 | 43 | 291 | 63.1 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -21.9 | 7.98 | -0.658 | 170 | -59.9 |